Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 6/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914480 | 0.77 | MAPT (0.46) | SLC9A1KEAP1KDM4ETSHRHSD17B10 | |
| SCHEMBL17831574 | 0.76 | MPO (0.42) | SLC9A1KEAP1KDM4ETSHRHSD17B10 | |
| SCHEMBL13067164 | 0.76 | ESR2 (0.49) | SLC9A1KEAP1KDM4ETSHRHSD17B10 | |
| SCHEMBL2673505 | 0.76 | SLC9A1 (0.42) | SLC9A1KEAP1KDM4ETSHRHSD17B10 | |
| SCHEMBL28729684 | 0.76 | KDM4E (0.41) | KDM4ETSHRHSD17B10GPR3MPO | |
| SCHEMBL20209699 | 0.76 | KDM4E (0.43) | KDM4ETSHRHSD17B10GPR3MPO | |
| SCHEMBL21508389 | 0.75 | NR1H2 (0.43) | NPC1RAB9ANR1H2NR1H3MAPT | |
| SCHEMBL15345099 | 0.74 | LMNA (0.40) | KDM4ETSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL12163 | 0.74 | KIT (0.41) | KDM4ETSHRHSD17B10ALDH1A1MAPT | |
| SCHEMBL7580249 | 0.74 | KDM5A (0.48) | SLC9A1KEAP1KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028495-B | The preparation method of pazopanib hydrochloride | 济南爱思医药科技有限公司 | 2019-12-03 | — | — | CN | claimed |
| CN-110028495-A | The environment-friendly preparation method thereof of pazopanib hydrochloride | 济南爱思医药科技有限公司 | 2019-07-19 | — | — | CN | claimed |
| CN-103450085-A | Preparation method of pazopanib hydrochloride key intermediate | ASYMCHEM LAB TIANJIN CO LTD | 2013-12-18 | — | — | CN | claimed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2025-10-16 | — | — | US | disclosed |
| US-20240228523-A1 | Metal complexes | UDC IRELAND LTD (IE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228523-A1 | Metal complexes | UDC IRELAND LTD (IE) | 2024-07-11 | — | — | US | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230192695-A1 | THERMALLY ASSISTED DELAYED FLUORESCENT MATERIALS WITH TRIAD-TYPE MATERIALS | UNIV ARIZONA STATE (US) | 2023-06-22 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| CN-1852897-A | Gamma-aminobutyric acid modulators | ROCHE PALO ALTO LLC (CH) | 2006-10-25 | — | — | CN | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, SMN1; SMN2, ADRM1 | SLC9A1 4581/4885KEAP1 1082/4885KDM4E 3435/4885 |
| US-20240228523-A1 | Metal complexes | MCU, IMMT, SOD1 | SLC9A1 1999/4885KEAP1 3435/4885KDM4E 4540/4885 |
| US-20230192695-A1 | THERMALLY ASSISTED DELAYED FLUORESCENT MATERIALS WITH TRIAD-TYPE MATERIALS | TTPA, TTC14, AAAS | SLC9A1 3527/4885KEAP1 1584/4885KDM4E 3740/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | SLC9A1 108/4885KEAP1 3122/4885KDM4E 2085/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | SLC9A1 1575/4885KEAP1 3853/4885KDM4E 1710/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | SLC9A1 4274/4885KEAP1 2746/4885KDM4E 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.